+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
PPLPHARMA

Piramal Pharma Share Price

₹194.44 -3.29 (-1.66%)
46.97% Gain from 52W Low

19 Oct, 2026 3:58 PM (IST)

Piramal Pharma live price: ₹194.44. It opened at ₹197 vs previous close ₹198; intraday high/low: ₹202/₹194. The 50 & 200 DMA stand at ₹201.30/₹187.60.

Piramal Pharma Performance

  • Today's Low
  • ₹194
  • Today's High
  • ₹202
  • 52 Week Low
  • ₹132
  • 52 Week High
  • ₹232
  • Open Price₹197
  • Previous Close₹198
  • Volume1,370,411
  • 50 DMA₹201.30
  • 100 DMA₹194.30
  • 200 DMA₹187.60

Piramal Pharma Chart

Investment Returns

  • Over 1 Month -6.59%
  • Over 3 Month + 8.37%
  • Over 6 Month + 30.63%
  • Over 1 Year + 0.93%

Smart Investing Starts Here Start SIP with Piramal Pharma for Steady Growth!

Invest Now

Piramal Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -82.5
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 25,887
  • P/B Ratio
  • 3.2
  • Average True Range
  • 6.4
  • EPS
  • -2.4
  • Dividend Yield
  • 0
  • MACD Signal
  • -3.6
  • RSI
  • 40.66
  • MFI
  • 50.64

Latest Stock News Updates

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Please find enclosed intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Piramal Pharma Ltd - 543635 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Half Year Ended 30Th September, 2026

Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter and half year ended 30th September, 2026

Piramal Pharma cuts exposure to Chinese raw materials to reduce supply risk

Piramal is among global drugmakers increasingly seeking to reduce their reliance on China for pharmaceutical ingredients and manufacturing, amid rising geopolitical tensions

Piramal Pharma Financials

Piramal Pharma Technicals

EMA & SMA

Current Price
₹194.44
-3.29 (-1.66%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹200.40
  • 50 Day
  • ₹201.30
  • 100 Day
  • ₹194.30
  • 200 Day
  • ₹187.60

Resistance and Support

196.65 Pivot Speed
  • R3 207.40
  • R2 204.60
  • R1 199.50
  • S1 191.60
  • S2 188.70
  • S3 183.70

Piramal Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-10-27 Quarterly Results
2026-07-29 Quarterly Results
2026-04-28 Audited Results
2026-01-28 Quarterly Results
2025-11-05 Quarterly Results
Date Purpose Remarks
2025-07-16 FINAL Rs.0.14 per share(1.4%)Final Dividend
2024-07-12 FINAL Rs.0.11 per share(1.1%)Final Dividend
View Piramal Pharma Dividend History Arrow

Piramal Pharma Shareholding Pattern

37.62%
34.8%
13.18%
12.51%
1.39%

About Piramal Pharma

Piramal Pharma perates as a pharmaceutical company. The Company manufactures and develops a wide range of pharmaceutical solutions to reduce diseases. View More
  • NSE Symbol
  • PPLPHARMA
  • BSE Symbol
  • 543635
  • ISIN
  • INE0DK501011

Similar Stocks to Piramal Pharma

Piramal Pharma FAQs

Piramal Pharma share price is ₹194 As on 19 October, 2026 | 22:42

The Market Cap of Piramal Pharma is ₹25886.7 Cr As on 19 October, 2026 | 22:42

The P/E ratio of Piramal Pharma is -82.5 As on 19 October, 2026 | 22:42

The PB ratio of Piramal Pharma is 3.2 As on 19 October, 2026 | 22:42

The 52 week High & Low of Piramal Pharma is ₹231.9/₹132.3 respectively As on 19 October, 2026 | 22:42

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23